The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure.
Haematologica
; 91(11): 1555-8, 2006 Nov.
Article
em En
| MEDLINE
| ID: mdl-17082013
ABSTRACT
Patients with multiple myeloma and end-stage renal failure on dialysis are frequently not considered eligible for high-dose therapy (HDT) due to higher transplant-related mortality (TRM). Our aim was to evaluate the toxicity and survival of dialysis-dependent patients after HDT with melphalan (100 mg/m(2)) compared to those of patients without renal insufficiency (melphalan 200 mg/m(2)) in a matched pairs analysis of 34 patients. No significant differences were observed between hematologic toxicity, TRM or disease response. Dialysis patients showed comparable event-free and overall survival. They required significantly extended intravenous antibiotic treatment and longer hospitalization. Thus, melphalan 100 mg/m2 is less toxic, yet equally efficient and improves the prognosis of this group of patients.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Diálise Renal
/
Transplante de Células-Tronco
/
Falência Renal Crônica
/
Mieloma Múltiplo
Limite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2006
Tipo de documento:
Article